Barbara Tate

Ingenuity Systems, Inc. provides intuitive web-based applications for quickly analyzing and accurately interpreting the biological meaning of genomics data. The company was founded in 1998 and is headquartered in Redwood City, CA.

Connective Orthopaedics, Inc. provides surgical and medical instruments. The company is headquartered in Waltham, MA.

MPM Bioimpact Inc (MPM Capital) is a venture capital firm founded in 1996 by Ansbert K. Gadicke and Luke B. Evnin. The firm is headquartered in Boston, Massachusetts.

McKinsey & Co., Inc. provides management consulting services. It specializes in design, marketing and sales, analytics, operations, transformation and restructuring, risk, strategy and corporate finance, and sustainability and resource productivity. The company was founded by James O. McKinsey in 1926 and is headquartered in New York, NY.

Oxagen Ltd. develops novel molecule drugs to treat inflammatory and respiratory diseases. It offers OC000459, an oral CRTH2 antagonist for the treatment of eosinophilic asthma and allergic rhino conjunctivitis. The company was founded by Nick Cross, John Irving Bellin, Mark Edwards, Trevor J. Nicholls and Ian Michael Laing on September 05 1996 and is headquartered in London, the United Kingdom.

Part of International Business Machines Corp., Wilkerson Group is a consulting company that provides services to the pharmaceutical and medical products industry. The company is based in New York, NY. The company was founded by Kenneth D. Noonan. The CEO is Neil MacAllister. Wilkerson Group was acquired by International Business Machines Corp. on April 01, 1996.

ESBATech AG develops antibody fragment therapeutics. The firm's antibody fragment is derived from human antibody fragment scaffolds. It develops Immuna, an antigen-independent platform to screen, select, and optimize highly-stable and soluble, single-chain antibody fragments. The company was founded by Dominik Escher in September 1998 and is headquartered Schlieren, Switzerland.

Puretech Health LLC (PureTech Ventures) is a venture capital subsidiary of PureTech Health Plc founded in 2000 by Daphne Zohar, Robert Langer and Ben Shapiro. The firm is headquartered in Boston, Massachusetts.

Karus Therapeutics Ltd. provides therapies for treatment of cancer and inflammatory diseases. It offers HDAC6 and PI3K inhibitors for the treatment of cancer. The firm’s products in pipeline include KA-2237, KAR4000 Series and KAR3000 Series for the treatment of chronic inflammation, haematological malignancies, and solid tumours. The company was founded in July 2005 by Arasu Ganesan, Graham Keith Packham and Paul Townsend and is headquartered in Abingdon, the United Kingdom.

Norwich Ventures Management LLC (Norwich Ventures) is a venture capital firm founded in 2004 by Aaron Sandoski and Marlin Miller. The firm is headquartered in Wyomissing, Pennsylvania.

Enlight Biosciences LLC develops research tools for drug discovery and development. It offers patient-centric platforms that may impact all aspects of the connected health ecosystem from patient engagement and experience, to patient-focused research and development. The company was founded by Raju S. Kucherlapati, David Steinberg, Rakesh Kumar Jain, H. Robert Horbitz, and Sanjiv Sam Gambhir in July 2008 and is headquartered in Boston, MA.

SV Health Managers LLP (SVHM) is the investment management subsidiary of SV Life Sciences Advisers LLP in the UK. Established in 2005, the firm was formerly known as SV Life Sciences Managers LLP and changed their name to SV Health Managers LLP in 2017. Based in London, the firm manages the International Biotechnology Trust plc (LSE: IBT), an investment trust vehicle listed on the London Stock Exchange into which corporate and private investors may invest.

Cell Medica Switzerland AG engages in the research, development, production, and distribution of pharmaceutical, biological, medical, and diagnostic products. It provides locally and systemically applied antibody therapeutics under the PENTRA Body platform. The company was founded by Thomas O. Hecht on September 4, 2009 and is headquartered in Schlieren, Switzerland.

Second Genome, Inc. develops microbiome-based therapeutic products. It offers phyclochip community, 16S sequencing community analysis, whole metagenomic profiling, nucleic acid isolation, inferred function and custom informatics services. The company was founded in 2009 by Corey S. Goodman, Janet A. Warrington, Todd Z. DeSantis, John Hulls and Gary Andersen and is headquartered in South San Francisco, CA.

Cerevance, Inc. provides pharmaceutical services. The firm discovers new treatments for central nervous system diseases. Its platform enables to profile specific brain cell types including both neurons and glial cells in mature human brain tissue. The company was founded by Bradley A. Margus and Mark Carlton in 2016 and is headquartered in Boston, MA.

ShangPharma Innovation Inc. (ShangPharma Innovation) is a venture capital firm, a subsidiary of Shangpharma Investment Group Ltd. founded in 2016. The firm is headquartered in San Francisco, California.

Lifeforce Capital Management, LLC (Lifeforce Capital) is a venture capital firm founded in 2015 by John Noonan. The firm is headquartered in Chevy Chase, Maryland.

QurAlis Corp. engages in discovering and developing new therapies for amyotrophic lateral sclerosis and other neurological diseases. It offers therapeutic programs and targets, and biomarkers. The company was founded by Clifford Woolf, Kevin Eggan, Jonathan J. Fleming, and Kasper Roet and is headquartered in North Cambridge, MA.

Weatherden Ltd. is a pioneering clinical development consulting group based in London, UK. The British company specializes in scientific strategy, translational medicine, clinical development, diligence preparation, and support for M & A. Weatherden focuses on de-risking programs early and optimizing clinical, regulatory, and commercial pathways to bring life-changing medicines to patients. With over 750 years of combined industry experience, they are dedicated to improving the chances for breakthrough therapies to address unmet clinical needs. The private company, founded by Duncan McHale and Houman Ashrafian, provides trusted advice to biopharma, funds, startups, spin-outs, and nonprofits. Emma Tinsley has been the CEO of the company since 2017.

Imbria Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company developing novel therapies that restore cellular energy deficits. It focuses on restoring or improving the cell?s ability to produce energy where energy imbalances are at the root of disease, including cardiovascular diseases and inborn errors of metabolism. The company was founded by Andrew Levin and David-Alexandre C. Gros in 2018 and is headquartered in Boston, MA.

Sitryx Therapeutics Ltd. Focuses on regulating cell metabolism to develop disease-modifying therapeutics in immuno-oncology and immuno-inflammation. It treats cancer and inflammatory conditions by targeting the metabolism of immune cells. The company was founded by Houman Ashrafian, Paul-Peter Tak, Luke O'Neill, Jonathan Powell, Jeff Rathmell and Michael Rosenblum and is headquartered in London, the United Kingdom.

Ervaxx Ltd. is a British company that pioneers the use of dark antigens to deliver targeted immunotherapies for treating and preventing cancer. The company was founded in 2016 by George Kassiotis, Drew M. Pardoll and is based in London, UK. The company's powerful, proprietary edapt platform has been developed to discover and validate dark antigens providing an in-depth assessment of candidate antigens on primary tumor cells along with their immunogenic potential. Ervaxx is advancing a pipeline of T cell receptor-based therapies, off-the-shelf cancer vaccines, and other immunotherapies leveraging these insights into the role of dark antigens in cancer.

Therini Bio, Inc. engages in research and development in the field of biotechnology. The company was founded by Katerina Akassoglou in 2016 and is headquartered in San Francisco, CA.

Sonoma Biotherapeutics, Inc. provides research, development, and manufacturing capabilities in cell therapy and genetic engineering. The company was founded by Jeffrey A. Bluestone, Fred Ramsdell, Alexander Rudensky, and Qizhi Tang in 2019 and is headquartered in South San Francisco, CA.

Alchemab Therapeutics Ltd. engages in developing of antibodies. It focuses on discovering and developing novel therapeutics for patients. The company was founded in 2019 and is headquartered in Kings Cross, the Unite Kingdom.

Zarodex Therapeutics Ltd. engages in the research and experimental development on biotechnology. The company was founded on July 26, 2017 and is headquartered in London, the United Kingdom.

Mestag Therapeutics Ltd. is engaged in the biotechnology industry. The company was founded on February 17, 2020 and is headquartered in Cambridge, the United Kingdom.

Loqus23 Therapeutics Ltd.engages in research and development of biotechnology. The company was founded on March 29, 2019 and is headquartered in in Reading, the United Kingdom.

Cellinta Ltd. operates as a biotechnology firm. The company was founded on August 16, 2019 and is headquartered in Reading, the United Kingdom.

Cybele Therapeutics Ltd. engages in research and experimental development on biotechnology. The company was founded on August 23, 2019 and is headquartered in Reading, the United Kingdom.

Catamaran Bio, Inc. provides investment services. The company is headquartered in Delaware.

The American company was founded by Nick Johnson, Cheng Zhang, and Marcel van der Brug, with Cheng Zhang serving as the CEO since incorporation. Character Biosciences is focused on developing therapies for ophthalmic and other progressive polygenic diseases. The company has developed a platform that integrates genomics with longitudinal clinical data to select drug targets and match therapies to the right patients. Currently, Character Biosciences is advancing two lead drug discovery programs through preclinical development for dry age-related macular degeneration.

Eyebiotech Ltd. is a British clinical stage ophthalmology company that treats patients with sight-threatening diseases. The company is based in London, UK. Eyebiotech was founded in 2021 by David R. Guyer and Anthony P. Adamis. David R. Guyer has been the CEO since 2021.

Endlyz Therapeutics, Inc. is an American company that operates in the biotechnology industry.

Opal Biosciences, Inc. operates as a biotechnology company. The company is headquartered in New York, NY.